Elegantly simple, safe and effective

BlueWillow’s intranasal platform has demonstrated safety in well over 400 humans with additional human clinical testing in progress. This platform technology overcomes the safety hurdle that has slowed intranasal vaccine development for many years. Concerns stemming from earlier generation intranasal adjuvants led to focus on non-adjuvanted approaches that have proven disappointing in terms of the robustness and durability of the immune response.

BlueWillow’s proprietary emulsion technology is comprised of simple components including water, a natural oil, and a cationic surfactant safely used for decades in products such as mouthwash. The unique formulation approach isolates antigens within the emulsion until they are efficiently delivered to APCs (antigen-presenting-cells) for immune system processing. It’s an elegantly simple approach enabling safe and effective intranasal vaccination.